A small study of adults with the most common form of pancreatic cancer adds to evidence that patients with BRCA1 or BRCA2 gene mutations long linked to a high risk of breast cancer have poorer overall survival rates than ...
May 17, 2018
0
180
Small cell lung cancer (SCLC) accounts for 14 percent of all lung cancers and is often rapidly resistant to chemotherapy resulting in poor clinical outcomes. Treatment has changed little for decades, but a study at The University ...
Apr 15, 2018
0
8
An international team of researchers led by Hassan Beyzavi of the University of Arkansas, is studying the use of platinum and gold to enable more effective forms of chemotherapy.
Mar 15, 2018
0
2
The presence in advanced breast cancer of mutational signatures characteristic of homologous recombination deficiency (HRD) was associated with improved clinical outcomes to treatment with platinum-based chemotherapy.
Dec 19, 2017
0
3
A new combination therapy for the first line treatment of advanced non-squamous non-small-cell lung cancer (NSCLC) improves progression-free survival (PFS), according to results of the phase III IMpower150 trial presented ...
Dec 7, 2017
0
1
Durvalumab improves progression-free survival in patients with locally advanced, unresectable stage II lung cancer, according to late-breaking results from the phase III PACIFIC trial presented today at the ESMO 2017 Congress ...
Sep 11, 2017
0
12
Mature results from the KEYNOTE-045 trial to be presented today at the ESMO 2017 Congress in Madrid (1) have confirmed significantly longer survival in patients with advanced urothelial cancer who receive the checkpoint inhibitor ...
Sep 11, 2017
0
0
Ramucirumab plus docetaxel improves progression-free survival in patients with advanced or metastatic urothelial cancer who have progressed on platinum-based chemotherapy, according to late-breaking results from the phase ...
Sep 11, 2017
0
0
Nivolumab (trade name: Opdivo) has been approved since June 2017 for adults with squamous cell carcinoma of the head and neck. The drug is an option if platinum-based chemotherapy is not sufficiently effective against this ...
Sep 6, 2017
0
0
Findings from a phase III clinical trial of about 300 women may introduce PARP inhibitors as a new type of treatment for breast cancer. Compared to standard chemotherapy, the oral targeted medicine olaparib (Lynparza) reduced ...
Jun 5, 2017
0
4
